MONTREAL, June 5 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. , the global leader in cryotherapy products to treat cardiovascular disease, today announced that Jan Keltjens, President and CEO of CryoCath, will present at the Leerink Swann - Rhythm Revival: Atrial Fibrillation Roundtable Conference at the Grand Hyatt in New York City on Wednesday, June 6. Mr. Keltjens will be part of an expert panel on device based therapies for atrial fibrillation at 2:15 p.m., followed by a corporate presentation at 3:00 p.m. that will highlight Arctic Front(R), CryoCath’s minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal atrial fibrillation.
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes “forward-looking statements” that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath’s annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management’s Discussion and Analysis section.
CryoCath Technologies Inc.
CONTACT: For further information: visit our website at www.cryocath.com,or contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext.241, Fax: (416) 815-0080, E-mail: mmoore@equicomgroup.com
